Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine vs. Active Placebo for Suicidal Ideation in Depression
NCT02593643Phase 1Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Jan 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD) (4 arms), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 2 weeks. Started Jan 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT02593643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593643.